Home/Pipeline/EGFR Mutation Detection Assay

EGFR Mutation Detection Assay

Non-Small Cell Lung Cancer (NSCLC)

Assay Development/ValidationActive

Key Facts

Indication

Non-Small Cell Lung Cancer (NSCLC)

Phase

Assay Development/Validation

Status

Active

Company

Stilla Technologies

About Stilla Technologies

Stilla Technologies, founded in 2016 and based in Paris, is a leader in multiplex digital PCR technology. The company's core innovation is the Nio® platform, which offers 7-color detection, continuous loading, and high sample throughput, addressing key limitations in traditional dPCR and qPCR. Its technology is applied in critical areas such as cancer mutation detection, CRISPR quality control, and viral vector analytics, serving academic, clinical, and biopharmaceutical customers. In 2024, Stilla Technologies was acquired by Bio-Rad Laboratories, significantly enhancing its global commercial reach and resources.

View full company profile

Therapeutic Areas

Oncology Genetic Disorders Infectious Diseases

Other Non-Small Cell Lung Cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
OX-4224	OmRx Oncology	Phase 2	Active